Garrett Robinson

US Patent:

20220354938, Nov 10, 2022

Filed:

Jun 29, 2022

Appl. No.:

17/852669

Inventors:

- Austin TX, US
Erin WILLERT - Round Rock TX, US
Sangeetha RAJAGOPALAN - Round Rock TX, US
Garrett Lee ROBINSON - Austin TX, US
Brigitte BRIESCHKE - Austin TX, US
Jason KIM - Austin TX, US

International Classification:

A61K 39/00
A61K 47/68
C07K 14/25

Abstract:

The present invention provides cell-targeting molecules which can deliver a CD8+ T-cell epitope cargo to the MHC class I presentation pathway of a target cell. The cell-targeting molecules of the invention can be used to deliver virtually any CD8+ T-cell epitope from an extracellular space to the MHC class I pathway of a target cell, which may be a malignant cell and/or non-immune cell. The target cell can then display on a cell-surface the delivered CD8+ T-cell epitope complexed with MHC I molecule. The cell-targeting molecules of the invention have uses which include the targeted labeling and/or killing of specific cell-types within a mixture of cell-types, including within a chordate, as well as the stimulation of beneficial immune responses. The cell-targeting molecules of the invention have uses, e.g., in the treatment of a variety of diseases, disorders, and conditions, including cancers, tumors, growth abnormalities, immune disorders, and microbial infections.

US Patent:

20220281926, Sep 8, 2022

Filed:

May 17, 2022

Appl. No.:

17/746106

Inventors:

- Austin TX, US
Erin WILLERT - Round Rock TX, US
Garrett Lee ROBINSON - Austin TX, US
Sangeetha RAJAGOPALAN - Round Rock TX, US
Brigitte BRIESCHKE - Austin TX, US

International Classification:

C07K 14/25
C07K 19/00

Abstract:

The present invention relates to Shiga toxin A Subunit derived polypeptides and cell-targeting molecules comprising amino acid substitutions which equip the polypeptides with 1) de-immunization; 2) reduced, protease-cleavage sensitivity; and/or 3) a heterologous epitope cargo(s) while retaining Shiga toxin function(s), such as, e.g., potent cytotoxicity. Certain polypeptides of the invention exhibit reduced immunogenic potential in mammals and/or are capable of delivering an epitope to an MHC class molecule of a cell in which the polypeptide is present. Certain molecules comprising a polypeptide of the invention are well-tolerated by mammals while retaining one or more of the features mentioned above. The Shiga toxin polypeptides of the invention have uses as components of cell-targeting molecules for selectively killing specific cells; for selectively delivering cargos to specific cells, and as therapeutic and/or diagnostic molecules for treating and diagnosing a variety of conditions, including cancers, immune disorders, and microbial infections.

US Patent:

20220275030, Sep 1, 2022

Filed:

Jun 11, 2021

Appl. No.:

17/345576

Inventors:

- Austin TX, US
Erin Willert - Round Rock TX, US
Garrett Lee Robinson - Austin TX, US
Sangeetha Rajagopalan - Round Rock TX, US
Brigitte Brieschke - Austin TX, US

International Classification:

C07K 14/25
C07K 14/245
C12N 9/10
C12N 9/24
C12N 15/62
C07K 16/00
C07K 16/08
C07K 16/10
C07K 16/28
C07K 16/32

Abstract:

The present invention relates to Shiga toxin effector polypeptides with reduced antigenic and/or immunogenic potential. Immunogenicity can be a limitation for the repeated administration to mammals of proteins and polypeptides derived from Shiga toxins. The Shiga toxin effector polypeptides of the present invention have uses as components of therapeutics, diagnostics, and immunization materials. The cytotoxic proteins of the present invention have uses for selective killing of specific cell types and as therapeutics for the treatment of a variety of diseases, including cancers, immune disorders, and microbial infections. The proteins of the present invention also have uses for detecting specific cell types, collecting diagnostic information, and monitoring the treatment of a variety of diseases, such as, e.g., cancers, immune disorders, and microbial infections.

US Patent:

20210268085, Sep 2, 2021

Filed:

Apr 12, 2021

Appl. No.:

17/228579

Inventors:

- Austin TX, US
Erin WILLERT - Round Rock TX, US
Sangeetha RAJAGOPALAN - Round Rock TX, US
Garrett Lee ROBINSON - Austin TX, US
Brigitte BRIESCHKE - Austin TX, US
Jason KIM - Austin TX, US

Assignee:

Molecular Templates, Inc. - Austin TX

International Classification:

A61K 39/00
A61K 47/68
C07K 14/25

Abstract:

The present invention provides cell-targeting molecules which can deliver a CD8+ T-cell epitope cargo to the MHC class I presentation pathway of a target cell. The cell-targeting molecules of the invention can be used to deliver virtually any CD8+ T-cell epitope from an extracellular space to the MHC class I pathway of a target cell, which may be a malignant cell and/or non-immune cell. The target cell can then display on a cell-surface the delivered CD8+ T-cell epitope complexed with MHC I molecule. The cell-targeting molecules of the invention have uses which include the targeted labeling and/or killing of specific cell-types within a mixture of cell-types, including within a chordate, as well as the stimulation of beneficial immune responses. The cell-targeting molecules of the invention have uses, e.g., in the treatment of a variety of diseases, disorders, and conditions, including cancers, tumors, growth abnormalities, immune disorders, and microbial infections.

US Patent:

20210253649, Aug 19, 2021

Filed:

Apr 19, 2021

Appl. No.:

17/233911

Inventors:

- Austin TX, US
Erin Willert - Round Rock TX, US
Garrett Lee Robinson - Austin TX, US
Sangeetha Rajagopalan - Round Rock TX, US
Brigitte Brieschke - Austin TX, US

International Classification:

C07K 14/25
C07K 19/00

Abstract:

The present invention relates to Shiga toxin A Subunit derived polypeptides and cell-targeting molecules comprising amino acid substitutions which equip the polypeptides with 1) de-immunization; 2) reduced, protease-cleavage sensitivity; and/or 3) a heterologous epitope cargo(s) while retaining Shiga toxin function(s), such as, e.g., potent cytotoxicity. Certain polypeptides of the invention exhibit reduced immunogenic potential in mammals and/or are capable of delivering an epitope to an MHC class molecule of a cell in which the polypeptide is present. Certain molecules comprising a polypeptide of the invention are well-tolerated by mammals while retaining one or more of the features mentioned above. The Shiga toxin polypeptides of the invention have uses as components of cell-targeting molecules for selectively killing specific cells; for selectively delivering cargos to specific cells, and as therapeutic and/or diagnostic molecules for treating and diagnosing a variety of conditions, including cancers, immune disorders, and microbial infections.

US Patent:

20200024312, Jan 23, 2020

Filed:

Jan 24, 2018

Appl. No.:

16/480591

Inventors:

- Austin TX, US
Erin WILLERT - Round Rock TX, US
Garrett Lee ROBINSON - Austin TX, US
Brigitte BRIESCHKE - Austin TX, US
Jason KIM - Austin TX, US

Assignee:

MOLECULAR TEMPLATES, INC. - Austin TX

International Classification:

C07K 14/25
A61K 47/68

Abstract:

The present invention provides cell-targeting molecules which can deliver a CD8+ T-cell epitope cargo to the MHC class I presentation pathway of a target cell. The cell-targeting molecules of the invention can be used to deliver virtually any CD8+ T-cell epitope from an extracellular space to the MHC class I pathway of a target cell, which may be a malignant cell and/or non-immune cell. The target cell can then display on a cell-surface the delivered CD8+ T-cell epitope complexed with MHC I molecule. The cell-targeting molecules of the invention have uses which include the targeted labeling and/or killing of specific cell-types within a mixture of cell-types, including within a chordate, as well as the stimulation of beneficial immune responses. The cell-targeting molecules of the invention have uses, e.g., in the treatment of a variety of diseases, disorders, and conditions, including cancers, tumors, growth abnormalities, immune disorders, and microbial infections.

US Patent:

20180258143, Sep 13, 2018

Filed:

May 27, 2016

Appl. No.:

15/577827

Inventors:

- Austin TX, US
Erin WILLERT - Round Rock TX, US
Garrett Lee ROBINSON - Austin TX, US
Sangeetha RAJAGOPALAN - Round Rock TX, US
Brigitte BRIESCHKE - Austin TX, US

Assignee:

Molecular Templates, Inc. - Austin TX

International Classification:

C07K 14/25
C07K 19/00

Abstract:

The present invention relates to Shiga toxin A Subunit derived polypeptides and cell-targeting molecules comprising amino acid substitutions which equip the polypeptides with 1) de-immunization; 2) reduced, protease-cleavage sensitivity; and/or 3) a heterologous epitope cargo(s) while retaining Shiga toxin function(s), such as, e.g., potent cytotoxicity. Certain polypeptides of the invention exhibit reduced immunogenic potential in mammals and/or are capable of delivering an epitope to an MHC class molecule of a cell in which the polypeptide is present. Certain molecules comprising a polypeptide of the invention are well-tolerated by mammals while retaining one or more of the features mentioned above. The Shiga toxin polypeptides of the invention have uses as components of cell-targeting molecules for selectively killing specific cells; for selectively delivering cargos to specific cells, and as therapeutic and/or diagnostic molecules for treating and diagnosing a variety of conditions, including cancers, immune disorders, and microbial infections.

US Patent:

20160340394, Nov 24, 2016

Filed:

Jan 26, 2015

Appl. No.:

15/114487

Inventors:

- Georgetown TX, US
Erin Willert - Round Rock TX, US
Garrett Lee Robinson - Austin TX, US
Sangeetha Rajagopalan - Round Rock TX, US
Brigitte Brieschke - Austin TX, US

Assignee:

Molecular Templates, Inc. - Georgetown TX

International Classification:

C07K 14/25
C07K 16/28
C07K 16/32
C12N 9/24
C07K 16/00
C07K 16/10
C12N 9/10
C07K 14/245
C07K 16/08

Abstract:

The present invention relates to Shiga toxin effector polypeptides with reduced antigenic and/or immunogenic potential. Immunogenicity can be a limitation for the repeated administration to mammals of proteins and polypeptides derived from Shiga toxins. The Shiga toxin effector polypeptides of the present invention have uses as components of therapeutics, diagnostics, and immunization materials. The cytotoxic proteins of the present invention have uses for selective killing of specific cell types and as therapeutics for the treatment of a variety of diseases, including cancers, immune disorders, and microbial infections. The proteins of the present invention also have uses for detecting specific cell types, collecting diagnostic information, and monitoring the treatment of a variety of diseases, such as, e.g., cancers, immune disorders, and microbial infections.